Ozempic on TikTok: separating hype from clinical fact

What did @dr.karanr actually say?

The surgeon behind this viral clip made three core arguments: that stopping semaglutide causes most people to regain lost weight, that the drug is lower-risk than bariatric surgery for appropriate patients, and that using it purely for cosmetic weight loss in healthy people is not a favorable trade-off given side effects like pancreatitis. He specifically cited "a study of almost two thousand adults" showing two-thirds of lost weight returns within a year of stopping. He also insisted that lifestyle changes are non-negotiable alongside the medication.

The framing is broadly responsible for a TikTok with 2.5 million views. He is not selling anything here, and he is not promising a quick fix. That matters when evaluating intent and risk of harm.

Does the science back this up?

Yes, on the weight regain point, pretty convincingly. The study he is referencing is almost certainly the STEP 1 extension trial published by Wilding et al. in 2022 in Diabetes, Obesity and Metabolism. Participants who completed the 68-week semaglutide trial and then stopped the drug regained approximately two-thirds of their prior weight loss within one year of withdrawal, with cardiometabolic markers also reverting toward baseline.

This finding has since been replicated in the SURMOUNT-4 trial for tirzepatide (Aronne et al., 2024, JAMA), which showed similar rebound dynamics after discontinuation. The emerging scientific consensus is that obesity involves dysregulated appetite signaling, and GLP-1 receptor agonists manage rather than resolve that dysregulation. Stopping the drug removes the management.

His point about pancreatitis is also grounded in real pharmacovigilance data. The FDA label for semaglutide carries a warning for acute pancreatitis, and post-marketing surveillance has flagged cases, though causality in individual patients remains difficult to establish. The absolute risk is low, but it is not zero.

What did they get right and wrong?

He gets the headline right. Weight regain after stopping semaglutide is well-documented and the two-thirds figure is consistent with published data. His framing that these medications treat a chronic disease and may therefore require chronic use is medically sound and aligns with how endocrinologists and obesity specialists actually discuss this class of drugs.

Where his argument gets slightly fuzzy is the comparison to bariatric surgery. He calls semaglutide "far less invasive" with a "far lower risk profile" than surgery, which is directionally true for acute procedural risk. But long-term data tells a more complicated story. Roux-en-Y gastric bypass produces more durable weight loss at 10 years than any GLP-1 trial has yet demonstrated, and for patients with severe obesity and diabetes, surgery has mortality benefit data that semaglutide does not yet have at that time horizon (Sjostrom et al., 2012, New England Journal of Medicine). The comparison is not as clean as the video implies.

He is also right to flag the risk-benefit problem for cosmetically motivated use in people with normal or near-normal BMI. This is an underreported issue. Trials that established semaglutide's efficacy enrolled patients with BMI above 27 with comorbidities or above 30. Extrapolating those findings to someone who wants to lose five kilos for aesthetics is not scientifically supported and introduces risk without proportionate benefit.

What should you actually know?

The most important thing this video gets right, even if indirectly, is that GLP-1 receptor agonists are chronic disease management tools, not a course of treatment with a defined end date. If you stop taking them, the physiological drivers of excess weight return. That is not a failure of willpower. It is pharmacology.

What it does not say clearly enough is that "lifestyle changes" is doing a lot of heavy lifting in that final sentence. Multiple trials show that exercise and dietary intervention improve but do not eliminate weight regain after GLP-1 discontinuation. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed sustained loss at two years, but only in patients who remained on the drug.

If you are considering semaglutide or any GLP-1 receptor agonist, the conversation with a qualified clinician should include your BMI, your metabolic comorbidities, your realistic ability to continue the medication long-term, and what stopping will mean for you. This is not a medication to start casually and stop when a target number appears on the scale.